Physician
Prime Healthcare Foundation - Southern Regional, LLC
Prime Healthcare Foundation - Southern Regional, LLC was paid $25.96M by Medicaid between Jan 2018 and Dec 2024, across 248 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoPRIME HEALTHCARE FOUNDATION - SOUTHERN REGIONAL, LLC
RIVERDALE, GA 30274
RIVERDALE, GA 30274
33aNPI1154795581assigned 11/23/2015
33bProvider typeCardiovascular Disease Physician
28Total paid$25.96M
24GClaims703,790
24DCodes billed248
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiovascular Disease Physician providers in Georgia
Rank by total paid#1 of 22
Median peer was paid$4K
This provider vs. median6,026×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,408 | $4.13M | |
| 2019 | 136,372 | $5.08M | |
| 2020 | 112,969 | $3.33M | |
| 2021 | 100,181 | $3.26M | |
| 2022 | 92,381 | $3.51M | |
| 2023 | 91,877 | $4.41M | |
| 2024incomplete | 50,602 | $2.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 25,634 | 22,426 | $5.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 28,597 | 25,466 | $3.59M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 11,601 | 10,076 | $3.34M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 3,250 | 2,865 | $1000K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.8% | 12,689 | 11,553 | $985K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 5,984 | 5,273 | $951K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 12,229 | 10,387 | $752K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.5% | 2,150 | 1,925 | $659K |
| 59025 | Fetal non-stress test | 2.1% | 6,918 | 5,597 | $547K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 16,403 | 12,899 | $426K |
| G0378 | Hospital observation service, per hour | 1.6% | 3,570 | 2,447 | $412K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 9,421 | 7,405 | $408K |
236 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 11,028 | $390K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 9,428 | $374K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 8,692 | $350K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 12,929 | $344K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 5,098 | $322K |
| 71045 | Radiologic examination, chest; single view | 1.0% | 8,970 | $262K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 4,105 | $233K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,072 | $228K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,137 | $227K |
| 76801 | <1% | 3,124 | $225K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 43,274 | $223K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 962 | $217K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,324 | $210K |
| 80053 | Comprehensive metabolic panel | <1% | 28,040 | $205K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,424 | $202K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,519 | $190K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,353 | $171K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,696 | $169K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,317 | $166K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,785 | $151K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,459 | $121K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,963 | $116K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,967 | $109K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,814 | $99K |
| 84484 | <1% | 12,984 | $99K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,493 | $84K |
| 96376 | <1% | 3,891 | $81K | |
| 73030 | <1% | 1,194 | $78K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 722 | $72K |
| 83880 | <1% | 3,150 | $72K | |
| 81001 | <1% | 31,281 | $69K | |
| 73562 | <1% | 1,264 | $64K | |
| 72100 | <1% | 1,221 | $64K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,261 | $60K |
| 80320 | <1% | 5,313 | $56K | |
| 73610 | <1% | 758 | $55K | |
| 83690 | <1% | 8,891 | $43K | |
| 84702 | <1% | 7,020 | $42K | |
| 80329 | <1% | 2,640 | $41K | |
| 81025 | <1% | 8,332 | $41K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 111 | $40K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,375 | $40K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 383 | $40K |
| 84703 | <1% | 7,284 | $37K | |
| 86901 | <1% | 5,329 | $37K | |
| 73630 | <1% | 827 | $35K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,059 | $34K |
| 86850 | <1% | 3,627 | $33K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 478 | $33K |
| 85027 | <1% | 6,863 | $30K | |
| 73130 | <1% | 442 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 57,819 | $25K |
| 93971 | <1% | 264 | $22K | |
| 87400 | <1% | 2,109 | $20K | |
| J3490 | Unclassified drugs | <1% | 4,687 | $20K |
| 85730 | <1% | 5,674 | $20K | |
| 85610 | <1% | 8,121 | $19K | |
| 82962 | <1% | 12,088 | $19K | |
| 83735 | <1% | 4,696 | $19K | |
| 43235 | <1% | 63 | $19K | |
| 76830 | Ultrasound, transvaginal | <1% | 256 | $18K |
| 97162 | <1% | 221 | $18K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 231 | $18K |
| 82140 | <1% | 2,268 | $17K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,979 | $17K |
| 72040 | <1% | 452 | $17K | |
| 88342 | <1% | 290 | $16K | |
| 84112 | <1% | 280 | $16K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 212 | $16K |
| 95811 | <1% | 24 | $16K | |
| 87116 | <1% | 1,886 | $16K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 475 | $16K |
| 90715 | <1% | 823 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,211 | $15K |
| 80074 | <1% | 432 | $15K | |
| 80061 | Lipid panel | <1% | 1,935 | $15K |
| 85379 | <1% | 2,121 | $14K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,549 | $14K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 293 | $13K |
| 86900 | <1% | 5,327 | $13K | |
| 87040 | <1% | 2,364 | $12K | |
| 74018 | <1% | 432 | $12K | |
| 70486 | <1% | 50 | $12K | |
| 82805 | <1% | 551 | $12K | |
| 87430 | <1% | 1,495 | $11K | |
| 74022 | <1% | 202 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,399 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,448 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 614 | $10K |
| APT15 | <1% | 841 | $9K | |
| 82550 | <1% | 3,827 | $8K | |
| 82553 | <1% | 1,086 | $7K | |
| 80076 | <1% | 1,921 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,445 | $6K |
| 10060 | <1% | 71 | $6K | |
| 73502 | <1% | 166 | $6K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 54 | $6K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 429 | $6K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 576 | $5K |
| 76937 | <1% | 104 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 534 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,599 | $5K |
| 93975 | <1% | 30 | $5K | |
| 87186 | <1% | 816 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,596 | $5K |
| 12001 | <1% | 76 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,265 | $4K |
| 11045 | <1% | 75 | $4K | |
| 82565 | <1% | 1,216 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,962 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,355 | $4K |
| 87076 | <1% | 693 | $4K | |
| 73560 | <1% | 78 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 113 | $4K |
| 73120 | <1% | 42 | $4K | |
| 85007 | <1% | 4,409 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,597 | $4K |
| 73110 | <1% | 70 | $4K | |
| 83605 | <1% | 629 | $4K | |
| 83615 | <1% | 923 | $4K | |
| 84550 | <1% | 1,022 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 484 | $3K |
| 88307 | <1% | 28 | $3K | |
| 93970 | <1% | 29 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 315 | $3K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 858 | $3K |
| 84439 | <1% | 476 | $3K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,847 | $3K |
| 81003 | <1% | 1,873 | $3K | |
| 82947 | <1% | 1,184 | $3K | |
| 94760 | <1% | 1,160 | $3K | |
| 93017 | <1% | 29 | $3K | |
| 87210 | <1% | 928 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,972 | $3K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 104 | $2K |
| 80164 | <1% | 255 | $2K | |
| 29515 | <1% | 71 | $2K | |
| 86703 | <1% | 202 | $2K | |
| 84460 | <1% | 602 | $2K | |
| 84450 | <1% | 605 | $2K | |
| 29125 | <1% | 69 | $2K | |
| 82803 | <1% | 176 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 433 | $2K |
| 82731 | <1% | 44 | $2K | |
| 12011 | <1% | 36 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 152 | $2K |
| 96367 | <1% | 89 | $2K | |
| 74019 | <1% | 49 | $2K | |
| 73090 | <1% | 26 | $2K | |
| 74220 | <1% | 13 | $2K | |
| 87340 | <1% | 185 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,567 | $2K |
| 97161 | <1% | 50 | $2K | |
| 73590 | <1% | 37 | $1K | |
| 29505 | <1% | 46 | $1K | |
| 87081 | <1% | 276 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 510 | $1K |
| 82728 | <1% | 141 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,940 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,683 | $1K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,989 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,046 | $1K |
| 86803 | <1% | 174 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,078 | $1K |
| 77065 | Tomosynthesis, mammo | <1% | 19 | $1K |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 526 | $1K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 22 | $1K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 41 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,027 | $972.37 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 18 | $924.70 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 13 | $888.84 |
| 82607 | <1% | 54 | $848.78 | |
| 86140 | <1% | 243 | $835.94 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,632 | $784.99 |
| APT09 | <1% | 79 | $762.24 | |
| 86762 | <1% | 57 | $704.41 | |
| 73140 | <1% | 13 | $680.45 | |
| 82150 | <1% | 129 | $663.63 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 587 | $647.24 |
| 86780 | <1% | 212 | $610.86 | |
| 85018 | <1% | 556 | $592.37 | |
| 94644 | <1% | 53 | $577.66 | |
| 85014 | <1% | 547 | $560.57 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 310 | $549.56 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 35 | $534.43 |
| 82248 | <1% | 136 | $530.90 | |
| 73600 | <1% | 13 | $487.58 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 290 | $402.80 |
| J1815 | Injection, insulin, per 5 units | <1% | 448 | $364.82 |
| 82570 | <1% | 75 | $364.50 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 35 | $355.34 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 117 | $351.84 |
| 83718 | <1% | 31 | $332.68 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 97 | $329.60 |
| 84100 | <1% | 301 | $293.82 | |
| 84520 | <1% | 132 | $288.31 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 80 | $268.21 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 129 | $244.07 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 375 | $232.89 |
| 84156 | <1% | 67 | $229.98 | |
| 87077 | <1% | 51 | $207.75 | |
| 86787 | <1% | 14 | $196.68 | |
| APT16 | <1% | 14 | $173.88 | |
| 99406 | <1% | 14 | $170.10 | |
| 80047 | <1% | 16 | $142.10 | |
| 83020 | <1% | 12 | $140.92 | |
| 87420 | <1% | 15 | $140.27 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 46 | $139.71 |
| A4217 | Sterile water/saline, 500 ml | <1% | 31 | $137.61 |
| 84145 | <1% | 23 | $133.73 | |
| 82247 | <1% | 32 | $131.33 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 124 | $129.44 |
| C1769 | Guide wire | <1% | 62 | $126.39 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 77 | $126.11 |
| 85670 | <1% | 31 | $105.75 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 105 | $93.35 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 54 | $70.90 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 20 | $51.58 |
| 84132 | <1% | 35 | $39.62 | |
| 87641 | <1% | 12 | $27.60 | |
| 82009 | <1% | 14 | $24.91 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 242 | $22.08 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 97 | $19.52 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 732 | $19.28 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 35 | $17.42 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 50 | $15.02 |
| 85049 | <1% | 15 | $13.44 | |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 165 | $12.92 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 20 | $7.87 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 19 | $7.37 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 100 | $2.77 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 29 | $2.68 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 20 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.